Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
September 14, 2023 11:37 ET
|
Spherix Global Insights
Exton, Pennsylvania, Sept. 14, 2023 (GLOBE NEWSWIRE) -- This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic US immunology...
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
August 31, 2023 16:35 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent...
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
June 27, 2023 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
St. Jude Children’s Research Hospital unveils 45,000-square-foot Family Commons [updated]
January 25, 2023 09:31 ET
|
St. Jude Children's Research Hospital
MEMPHIS, Tenn. and NORTH CHICAGO, Ill., Jan. 25, 2023 (GLOBE NEWSWIRE) -- St. Jude Children’s Research Hospital® and AbbVie, a research-based global biopharmaceutical company, today unveiled the...
St. Jude Children’s Research Hospital unveils 45,000-square-foot Family Commons
January 23, 2023 13:03 ET
|
St. Jude Children's Research Hospital
MEMPHIS, Tenn. and NORTH CHICAGO, Ill., Jan. 23, 2023 (GLOBE NEWSWIRE) -- St. Jude Children’s Research Hospital® and AbbVie, a research-based global biopharmaceutical company, today unveiled the...
AbbVie (ABBV) Alert: Johnson Fistel, Globally-Recognized Law Firm, Encourages Long-Term Shareholders to Submit Their Information
June 13, 2022 13:00 ET
|
Johnson Fistel, LLP
SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of AbbVie, Inc. (AbbVie) (NYSE: ABBV) against certain of its officers and directors. If...
ABBV FINAL DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors to Secure Counsel Before Important June 6 Deadline in Securities Class Action – ABBV
June 06, 2022 09:30 ET
|
The Rosen Law Firm PA
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August...
ABBVIE INC. (NYSE: ABBV) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AbbVie Inc. (NYSE: ABBV)
June 01, 2022 00:30 ET
|
Bernstein Liebhard LLP
Did you lose money on investments in AbbVie? If so, please visit AbbVie Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AbbVie, Playstudios, IBM, and Twitter and Encourages Investors to Contact the Firm
May 29, 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
(ABBV) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel, Globally-Recognized Law Firm about Leading AbbVie Inc. Class Action Lawsuit
May 28, 2022 10:19 ET
|
Johnson Fistel, LLP
SAN DIEGO, May 28, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of AbbVie Inc. (NYSE: ABBV) who...